In conclusion, this was the first study to identify the usefulness of a combined biomarker evaluation of sTNFR1 and IL-2 for the prediction of sustained remission for 2 years after bDMARD discontinuation in patients with RA. The gene discussed is IL2; the disease is rheumatoid arthritis.